- Home
- RUM vs DNTH Comparison
RUM vs DNTH Comparison
Compare RUM & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RUM
- DNTH
- Stock Information
- Founded
- RUM 2013
- DNTH 2015
- Country
- RUM United States
- DNTH United States
- Employees
- RUM N/A
- DNTH N/A
- Industry
- RUM Computer Software: Prepackaged Software
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- RUM Technology
- DNTH Health Care
- Exchange
- RUM Nasdaq
- DNTH Nasdaq
- Market Cap
- RUM 2.1B
- DNTH 1.8B
- IPO Year
- RUM N/A
- DNTH N/A
- Fundamental
- Price
- RUM $6.68
- DNTH $43.80
- Analyst Decision
- RUM Buy
- DNTH Strong Buy
- Analyst Count
- RUM 2
- DNTH 10
- Target Price
- RUM $15.00
- DNTH $68.00
- AVG Volume (30 Days)
- RUM 4.1M
- DNTH 737.7K
- Earning Date
- RUM 11-10-2025
- DNTH 11-05-2025
- Dividend Yield
- RUM N/A
- DNTH N/A
- EPS Growth
- RUM N/A
- DNTH N/A
- EPS
- RUM N/A
- DNTH N/A
- Revenue
- RUM $103,782,153.00
- DNTH $3,078,000.00
- Revenue This Year
- RUM $14.63
- DNTH N/A
- Revenue Next Year
- RUM $34.05
- DNTH N/A
- P/E Ratio
- RUM N/A
- DNTH N/A
- Revenue Growth
- RUM 21.17
- DNTH N/A
- 52 Week Low
- RUM $5.11
- DNTH $13.37
- 52 Week High
- RUM $17.40
- DNTH $44.27
- Technical
- Relative Strength Index (RSI)
- RUM 54.90
- DNTH 70.39
- Support Level
- RUM $5.31
- DNTH $39.82
- Resistance Level
- RUM $5.76
- DNTH $43.34
- Average True Range (ATR)
- RUM 0.41
- DNTH 2.64
- MACD
- RUM 0.12
- DNTH 0.63
- Stochastic Oscillator
- RUM 90.49
- DNTH 94.63
About RUM Rumble Inc.
Rumble Inc is a free-to-use video-sharing platform where users can watch, share, like, comment, and upload their own videos. Users can subscribe to channels to stay in touch with recent creator content and access video-on-demand uploaded, and live content streamed, by creators. Geographically, it generates a majority of its revenue from the United States.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.